206 related articles for article (PubMed ID: 38626341)
1. De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression.
Tangudu NK; Buj R; Wang H; Wang J; Cole AR; Uboveja A; Fang R; Amalric A; Yang B; Chatoff A; Crispim CV; Sajjakulnukit P; Lyons MA; Cooper K; Hempel N; Lyssiotis CA; Chandran UR; Snyder NW; Aird KM
Cancer Res Commun; 2024 May; 4(5):1174-1188. PubMed ID: 38626341
[TBL] [Abstract][Full Text] [Related]
2. De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression.
Tangudu NK; Buj R; Wang H; Wang J; Cole AR; Uboveja A; Fang R; Amalric A; Sajjakulnukit P; Lyons MA; Cooper K; Hempel N; Snyder NW; Lyssiotis CA; Chandran UR; Aird KM
bioRxiv; 2023 Sep; ():. PubMed ID: 37503050
[TBL] [Abstract][Full Text] [Related]
3. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
5. Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming.
Buj R; Chen CW; Dahl ES; Leon KE; Kuskovsky R; Maglakelidze N; Navaratnarajah M; Zhang G; Doan MT; Jiang H; Zaleski M; Kutzler L; Lacko H; Lu Y; Mills GB; Gowda R; Robertson GP; Warrick JI; Herlyn M; Imamura Y; Kimball SR; DeGraff DJ; Snyder NW; Aird KM
Cell Rep; 2019 Aug; 28(8):1971-1980.e8. PubMed ID: 31433975
[TBL] [Abstract][Full Text] [Related]
6. Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.
Lutful Kabir FM; DeInnocentes P; Bird AC; Bird RC
In Vitro Cell Dev Biol Anim; 2021 May; 57(5):519-530. PubMed ID: 34014456
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
8. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
[TBL] [Abstract][Full Text] [Related]
9. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.
Casula M; Muggiano A; Cossu A; Budroni M; Caracò C; Ascierto PA; Pagani E; Stanganelli I; Canzanella S; Sini M; Palomba G; ; Palmieri G
BMC Cancer; 2009 Oct; 9():352. PubMed ID: 19799798
[TBL] [Abstract][Full Text] [Related]
10. Loss of Both CDKN2A and CDKN2B Allows for Centrosome Overduplication in Melanoma.
Patel S; Wilkinson CJ; Sviderskaya EV
J Invest Dermatol; 2020 Sep; 140(9):1837-1846.e1. PubMed ID: 32067956
[TBL] [Abstract][Full Text] [Related]
11. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Ming Z; Lim SY; Rizos H
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
[TBL] [Abstract][Full Text] [Related]
12. Effects of CDKN2A (p16INK4A/p14ARF) Over-Expression on Proliferation and Migration of Human Melanoma A375 Cells.
Bai M; Yu NZ; Long F; Feng C; Wang XJ
Cell Physiol Biochem; 2016; 40(6):1367-1376. PubMed ID: 27997910
[TBL] [Abstract][Full Text] [Related]
13. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
Williams RT; Barnhill LM; Kuo HH; Lin WD; Batova A; Yu AL; Diccianni MB
PLoS One; 2014; 9(2):e88219. PubMed ID: 24505435
[TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor gene p16/INK4A/CDKN2A-dependent regulation into and out of the cell cycle in a spontaneous canine model of breast cancer.
Agarwal P; Sandey M; DeInnocentes P; Bird RC
J Cell Biochem; 2013 Jun; 114(6):1355-63. PubMed ID: 23238983
[TBL] [Abstract][Full Text] [Related]
15. Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line.
Frost SJ; Simpson DJ; Clayton RN; Farrell WE
Mol Endocrinol; 1999 Nov; 13(11):1801-10. PubMed ID: 10551774
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma.
Kreuger IZM; Slieker RC; van Groningen T; van Doorn R
J Invest Dermatol; 2023 Jan; 143(1):18-25.e1. PubMed ID: 36123181
[TBL] [Abstract][Full Text] [Related]
17. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
Chen ZH; Olopade OI; Savarese TM
Mol Pharmacol; 1997 Nov; 52(5):903-11. PubMed ID: 9351982
[TBL] [Abstract][Full Text] [Related]
18. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G; Rajadurai A; Tsao H
J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
[TBL] [Abstract][Full Text] [Related]
19. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Becker TM; Rizos H; Kefford RF; Mann GJ
Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
[TBL] [Abstract][Full Text] [Related]
20. A novel CDKN2A variant (p16
Li C; Liu T; Liu B; Hernandez R; Facelli JC; Grossman D
Pigment Cell Melanoma Res; 2019 Sep; 32(5):734-738. PubMed ID: 31001908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
